Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good afternoon. Thank you for joining us to discuss LifeMD, Inc.

LifeMD Inc (LFMD) reports a 43% revenue increase and unveils plans for new product launches and Medicare offerings amid ...

Full Year 2024 Results Key Financial Results Revenue: US$212.5m (up 39% from FY 2023). Net ...

H.C. Wainwright analyst Yi Chen raised the firm’s price target on LifeMD (LFMD) to $14 from $12 and keeps a Buy rating on the shares. The ...

In a report released on March 11, Steven Valiquette from Mizuho Securities maintained a Hold rating on LifeMD (LFMD – Research Report). The ...

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...

As the U.S. stock market grapples with political and economic uncertainty, leading to a correction in major indices like the S&P 500 and Nasdaq Composite, investors are increasingly seeking stability ...

Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug ...

LifeMD reported a fourth-quarter loss per share of 2 cents. Analysts were expecting a loss of 5 cents per share, according to FactSet. Revenue for the fourth quarter came in at $64.3 million. Analysts ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88. The company has a market capitalization of $241.25 million, a P/E ratio of -8.70 and a beta of 1.50.